文献速递心脑血管急症

替奈普酶与阿替普酶治疗急性缺血性卒中:ORIGINAL随机临床试验

Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01
一句话结论中国55家中心研究显示,症状发作4.5小时内急性缺血性卒中静脉溶栓,替奈普酶0.25 mg/kg在90天mRS 0–1非劣于阿替普酶0.9 mg/kg,安全性相似。

ORIGINAL研究为多中心、活性对照、平行分组、随机、开放标签、盲法终点、非劣效性试验,2021年7月14日至2023年7月14日在中国55家神经内科门诊和卒中中心纳入症状发作4.5小时内、NIHSS评分1–25分且有可测量神经功能缺损的急性缺血性卒中患者,1:1随机接受静脉替奈普酶0.25 mg/kg或阿替普酶0.9 mg/kg。全分析集1465例中,90天mRS 0–1分比例替奈普酶组72.7%(532/732)vs阿替普酶组70.3%(515/733),RR 1.03(95%CI 0.97–1.09),达到非劣效阈值(RR界值0.937)。症状性颅内出血两组各9例(1.2%),RR 1.01(95%CI 0.37–2.70);90天全因死亡率替奈普酶组4.6%(34/732)vs阿替普酶组5.8%(43/736),RR 0.80(95%CI 0.51–1.23)。作者认为替奈普酶可作为该场景下阿替普酶的合适替代。

要点

  • 中国55家中心、1489例随机,全分析集1465例;症状发作4.5小时内AIS,替奈普酶0.25 mg/kg静脉单次 bolus 对比阿替普酶0.9 mg/kg。
  • 90天mRS 0–1分:替奈普酶组72.7%(532/732)vs阿替普酶组70.3%(515/733),RR 1.03(95%CI 0.97–1.09),达到非劣效(RR界值0.937)。
  • 症状性颅内出血(ECASS III定义)两组各9例(1.2%),RR 1.01(95%CI 0.37–2.70)。
  • 90天全因死亡率替奈普酶组4.6%(34/732)vs阿替普酶组5.8%(43/736),RR 0.80(95%CI 0.51–1.23)。
  • 作者结论支持替奈普酶作为该场景下阿替普酶的合适替代。

适用人群与场景

  • 中国55家神经内科门诊和卒中中心收治的急性缺血性卒中患者,症状发作4.5小时内,NIHSS评分1–25分,有可测量神经功能缺损,症状持续至少30分钟且无显著改善。

诊断标准与关键阈值

  • 入组标准:急性缺血性卒中,NIHSS评分1–25分,有可测量神经功能缺损,症状持续至少30分钟无显著改善,症状发作4.5小时内。
  • 主要终点非劣效界值:风险比(RR)界值0.937。
  • 症状性颅内出血采用欧洲急性卒中协作研究III(ECASS III)定义。

处置流程与药物剂量

  • 症状发作4.5小时内1:1随机接受静脉替奈普酶0.25 mg/kg或静脉阿替普酶0.9 mg/kg。

研究设计与关键结果

  • 研究类型:多中心、活性对照、平行分组、随机、开放标签、盲法终点、非劣效性试验,2021年7月14日至2023年7月14日在中国55家神经内科门诊和卒中中心开展。
  • 样本量:随机1489例,全分析集1465例(替奈普酶组732例,阿替普酶组733例),女性446例(30.4%)。
  • 主要终点:90天mRS 0–1分比例替奈普酶组72.7%(532/732)vs阿替普酶组70.3%(515/733),RR 1.03(95%CI 0.97–1.09),达到非劣效阈值(RR界值0.937)。
  • 安全性终点:症状性颅内出血两组各9例(1.2%),RR 1.01(95%CI 0.37–2.70);90天全因死亡率替奈普酶组4.6%(34/732)vs阿替普酶组5.8%(43/736),RR 0.80(95%CI 0.51–1.23)。

证据类型、等级与局限

  • 证据类型:随机对照非劣效性试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在症状发作4.5小时内适合静脉溶栓的AIS患者中,替奈普酶在90天mRS 0–1分方面非劣于阿替普酶且安全性相似,研究结果支持替奈普酶作为该场景下阿替普酶的合适替代。

指南或共识出处

  • ORIGINAL随机临床试验,ClinicalTrials.gov注册号NCT04915729。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Tenecteplase is a bioengineered variant of alteplase with greater fibrin specificity and a longer half-life, allowing single-bolus administration. Evidence on the treatment effect of tenecteplase 0.25 mg/kg in Chinese patients with acute ischemic stroke (AIS) is limited.

OBJECTIVE: To establish the noninferiority of tenecteplase to alteplase in patients with AIS within 4.5 hours of symptom onset.

DESIGN, SETTING, AND PARTICIPANTS: The ORIGINAL study was a multicenter, active-controlled, parallel-group, randomized, open-label, blinded end point, noninferiority trial conducted between July 14, 2021, and July 14, 2023. Participants were recruited from 55 neurology clinics and stroke centers in China and were eligible if they had AIS with a National Institutes of Health Stroke Scale score of 1 to 25 with measurable neurologic deficit and were symptomatic for at least 30 minutes without significant improvement.

INTERVENTIONS: Patients were randomized (1:1) within 4.5 hours of symptom onset to receive intravenous tenecteplase (0.25 mg/kg) or intravenous alteplase (0.9 mg/kg).

MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with a modified Rankin Scale (mRS) score of 0 or 1 (no symptoms or no significant disability) at day 90, tested for noninferiority (risk ratio [RR] margin, 0.937). Safety end points included symptomatic intracerebral hemorrhage (per European Cooperative Acute Stroke Study III definition) and 90-day all-cause mortality.

RESULTS: Among the 1489 patients randomized, 1465 patients were included in the full analysis set (732 in the tenecteplase group; 733 in the alteplase group) and 446 (30.4%) were female. The primary outcome occurred in 72.7% (532/732) of patients receiving tenecteplase and 70.3% (515/733) receiving alteplase (RR, 1.03 [95% CI, 0.97-1.09]; noninferiority threshold met). Symptomatic intracerebral hemorrhage occurred in 9 patients (1.2%) in each group (RR, 1.01 [95% CI, 0.37-2.70]). The 90-day mortality rate was 4.6% (34/732) in the tenecteplase group and 5.8% (43/736) in the alteplase group (RR, 0.80 [95% CI, 0.51-1.23]).

CONCLUSIONS AND RELEVANCE: In patients with AIS eligible for intravenous thrombolysis within 4.5 hours after stroke onset, tenecteplase was noninferior to alteplase with respect to excellent functional outcome (mRS score of 0 or 1) at 90 days and had a similar safety profile. Findings from this study support tenecteplase as a suitable alternative to alteplase in this setting.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04915729.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Meng X, Li S, Dai H, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial. JAMA. 2024. PMID: 39264623. doi:10.1001/jama.2024.14721

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。